surmount-1 tirzepatide non-diabetic obesity trial weight loss Tirzepatide for Obesity: Highlights from the SURMOUNT-1 Tirzepatide cuts diabetes risk by

The medication is administered once weekly via subcutaneous injection, typically in the abdomen, thigh, or upper arm

This additional mechanism accounts for the 56 percentage point efficacy advantage

This is particularly valuable if you're experiencing irregular bowel movements or digestive discomfort

This weight loss was achieved when tirzepatide was combined with lifestyle changes, such as diet and exercise

I recommend that you continue to work with your provider to explore other reasons for diarrhea, review your dietary history, and step down on the dosage which you were able to tolerate or switch medications, as needed

This amount is designed to introduce the medication to your system gradually